PHI-101
Modify Date: 2025-09-22 01:26:33
PHI-101 structure
|
Common Name | PHI-101 | ||
|---|---|---|---|---|
| CAS Number | 2127107-15-5 | Molecular Weight | 386.44 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C19H19FN4O2S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PHI-101PHI-101 is an orally active FLT3 inhibitor that overcomes resistance to multiple drug-resistant mutations. PHI-101 potently inhibits FLT3 single activating mutations (ITD or TKD mutants) and has inhibitory activity against FLT3 double (ITD/D835Y or ITD/F691L) and triple (ITD/D835Y/F691L) resistance mutations. PHI-101 has potential for research in relapsed or refractory acute myeloid leukemia (AML)[1]. |
| Name | PHI-101 |
|---|
| Description | PHI-101 is an orally active FLT3 inhibitor that overcomes resistance to multiple drug-resistant mutations. PHI-101 potently inhibits FLT3 single activating mutations (ITD or TKD mutants) and has inhibitory activity against FLT3 double (ITD/D835Y or ITD/F691L) and triple (ITD/D835Y/F691L) resistance mutations. PHI-101 has potential for research in relapsed or refractory acute myeloid leukemia (AML)[1]. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C19H19FN4O2S |
|---|---|
| Molecular Weight | 386.44 |